Rh28Homo sapiens (Human)Cancer cell line
Also known as: SJRH28, SJRH 28, SJRH-28, Rh 28, Rh-28, RH28
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_8752 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Axillary lymph node[UBERON:UBERON_0001097] |
Donor Information
| Age | 17 |
|---|---|
| Age Category | Pediatric |
| Sex | Male |
Disease Information
| Disease | Alveolar rhabdomyosarcoma |
|---|---|
| Lineage | Soft Tissue |
| Subtype | Alveolar Rhabdomyosarcoma |
| OncoTree Code | ARMS |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-001740_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationNone reported | TP53 | - | - | - | PubMed=19787792 |
| MutationSimple | CDKN2A | p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT) | Unspecified | - | PubMed=23851445 |
| Gene fusion | FOXO1 | PAX3-FOXO1, PAX3-FKHR | - | Not found in original tumor | from parent cell line Rh30 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma.
Sala R., Heller M., Rossler J., Bernasconi M.
Int. J. Mol. Sci. 24:2601.1-2601.28(2023).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Harris E., Monks A., Morris J.
Mol. Cancer Ther. 14:2452-2462(2015).
A mass spectrometric-derived cell surface protein atlas.";
Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
PLoS ONE 10:E0121314-E0121314(2015).
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Linardic C.M.
Front. Oncol. 3:183.1-183.12(2013).
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Oncogene 33:1877-1889(2014).
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Borsu L., Barr F.G., Ladanyi M.
Clin. Cancer Res. 18:748-757(2012).
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Belyea B.C., Naini S., Bentley R.C., Linardic C.M.
Clin. Cancer Res. 17:7324-7336(2011).
Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.
Clin. Cancer Res. 6:4119-4127(2000).
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.
Cancer Res. 58:5009-5013(1998).
Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status.
Harris L.C.
Oncol. Res. 10:235-244(1998).
Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis.
Tapscott S.J., Thayer M.J., Weintraub H.M.
Science 259:1450-1453(1993).
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Rauscher F.J. 3rd, Emanuel B.S., Rovera G., Barr F.G.
Nat. Genet. 5:230-235(1993).
Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization.
Biegel J.A., Nycum L.M., Valentine V.A., Barr F.G., Shapiro D.N.
Genes Chromosomes Cancer 12:186-192(1995).
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma.
Torrance P.M., Holt H., Houghton P.J.
Cancer Res. 47:4501-4507(1987).